EXEL · Exelixis, Inc.
$55.37
+1.25% last session
End-of-day data · updated 2026-07-28
Market cap
$14B
Enterprise value
$13B
Trailing P/E
18.5
Forward P/E
13.8
Dividend yield
—
Beta
0.42
Avg volume
3M
Employees
1K
2D change
—
5D change
0.29%
10D change
-0.20%
30D change
1.90%
60D change
10.56%
MTD change
3.43%
YTD change
27.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — EXEL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$53.00
-4.3% vs priceBarclays
Equal-Weight$49.00
-11.5% vs priceWells Fargo
Equal-Weight$49.00
-11.5% vs priceRBC Capital
Sector Perform$46.00
-16.9% vs priceUBS
Neutral$52.00
-6.1% vs priceGoldman Sachs
Buy$47.00
-15.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Morgan Stanley | Maintains | Equal-Weight | $50.00 → $53.00 |
| 2026-07-14 | Barclays | Maintains | Equal-Weight | $45.00 → $49.00 |
| 2026-07-13 | Wells Fargo | Maintains | Equal-Weight | $40.00 → $49.00 |
| 2026-07-07 | RBC Capital | Maintains | Sector Perform | $43.00 → $46.00 |
| 2026-07-07 | Truist Securities | Maintains | Hold | $54.00 → $56.00 |
| 2026-07-02 | UBS | Maintains | Neutral | $43.00 → $52.00 |
| 2026-07-02 | HC Wainwright & Co. | Reiterates | Buy | $56.00 |
| 2026-06-25 | Truist Securities | Downgrade | Buy → Hold | $51.00 → $54.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.3% above the 50-day MA ($53.17).
- Price vs 200-day MA: Trading 24.3% above the 200-day MA ($45.46).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($57.10).
EXEL Price Chart
Loading chart for EXEL…
Fundamentals
About Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.